Kesai, enoxaparin sodium

  Xeroxi, commonly known as enoxaparin sodium injection. The main ingredient is enoxaparin, which is indicated for the prevention of venous thromboembolism and for the prevention of intravascular thrombosis, especially embolization related to certain operations, and is used in hemodialysis in extracorporeal circulation to prevent thrombosis.

  For the treatment of cardiac vein thrombosis, acute unstable angina pectoris, CQB myocardial infarction, use the same as aspirin, its dosage for the prevention of deep venous thrombosis, hyperglycemia, risk patients, adults, preoperative administration of 40 mg, followed by subcutaneous injection of 40 mg every 24 hours.

Kesai, enoxaparin sodium

  Risk of thrombosis patients were 2 hours to 20 mg, can then subcutaneously once every 24 hours, tell treatment should be continued for 10 to 14, or thrombosis risk disappeared, treatment with venous thrombosis give 1 mg per kilogram of body weight, subcutaneous drug every 12 hours for ten days, extracorporeal circulation such as dialysis all given a single dose of 1 mg per kilogram of body weight.

  The above dose is sufficient for a 4-hour dialysis course. If the dialysis is prolonged, an additional quarter of the above dose is required per hour. Unstable angina and non-Q wave myocardial infarction, onset within 24 hours, every 12 hours per kg body weight subcutaneous administration continued for 6 to 8 days until clinical symptoms stabilized.

  Its adverse reactions, such as thrombocytopenia, abnormal liver function, occasional changes in aminotransferase and alkaline phosphatase. Note for acute bacterial endocarditis, haemorrhage, thrombocytopenia, peptic ulcer, stroke, bleeding tendency.

  It should be noted that this drug should not be used with caution in patients with hepatic and renal insufficiency, uncontrolled arterial hypertension, peptic ulcer or pregnant women.